These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1981136)

  • 41. [Pyrazinobutazone in rheumatology (Clinical study of 50 cases)].
    Fournie A; Ayrolles C
    Rhumatologie; 1972; 24(7):287-91. PubMed ID: 4540383
    [No Abstract]   [Full Text] [Related]  

  • 42. [Experience in the use of salazopyrine EN in patients with spondylarthritis ankylopoietica and rheumatoid arthritis].
    Somhegyi A; Gömör B
    Orv Hetil; 1988 Sep; 129(36):1917-21. PubMed ID: 2902550
    [No Abstract]   [Full Text] [Related]  

  • 43. The use of sulphasalazine as a disease modifying antirheumatic drug.
    Porter DR; Capell HA
    Baillieres Clin Rheumatol; 1990 Dec; 4(3):535-51. PubMed ID: 1982707
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy.
    Akkoc N; van der Linden S; Khan MA
    Best Pract Res Clin Rheumatol; 2006 Jun; 20(3):539-57. PubMed ID: 16777581
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses].
    Manger B; Michels H; Nüsslein HG; Schneider M; Sieper J;
    Z Rheumatol; 2007 Feb; 66(1):72-5. PubMed ID: 17221253
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical study with a new phenylbutazone preparation in rheumatology].
    Marmont A; Rossi F
    Clin Ter; 1972 Oct; 63(1):17-51. PubMed ID: 4566104
    [No Abstract]   [Full Text] [Related]  

  • 47. [New basic preparations with prolonged action in the treatment of rheumatoid arthritis].
    Tumanova IG; Sigidin IaA
    Ter Arkh; 1987; 59(4):80-3. PubMed ID: 2884735
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pharmacological management of inflammatory rheumatic conditions].
    Bannwarth B
    Therapie; 2011; 66(5):377-81. PubMed ID: 22031680
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Experiences in the management of rheumatoid diseases using different clofezone doses].
    Celik CM
    Z Rheumatol; 1976; 35(5-6):240-7. PubMed ID: 133565
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Evaluation of the therapeutic action and tolerance of diphenpyramide in the treatment of rheumatic diseases].
    Cavazzuti F
    Clin Ter; 1977 Dec; 83(5):469-81. PubMed ID: 305328
    [No Abstract]   [Full Text] [Related]  

  • 51. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients.
    Dougados M; Boumier P; Amor B
    Br Med J (Clin Res Ed); 1986 Oct; 293(6552):911-4. PubMed ID: 2876744
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sulfasalazine in the rheumatic disease.
    Pinals RS
    Semin Arthritis Rheum; 1988 May; 17(4):246-59. PubMed ID: 2906760
    [No Abstract]   [Full Text] [Related]  

  • 53. [Therapy of inflammatory-rheumatic diseases with levamisol, an immunity modulating substance].
    Trabert U; Rosenthal M; Müller W
    Schweiz Med Wochenschr; 1976 Sep; 106(39):1293-301. PubMed ID: 1087457
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Basic therapeutics in the management of various forms of arthritis].
    Sieper J
    Orthopade; 1998 Aug; 27(8):576-80. PubMed ID: 9779434
    [No Abstract]   [Full Text] [Related]  

  • 55. Rheumatoid arthritis: a risk factor for sulphasalazine toxicity? A meta-analysis.
    Wijnands MJ; Van 'T Hof MA; Van De Putte LB; Van Riel PL
    Br J Rheumatol; 1993 Apr; 32(4):313-8. PubMed ID: 8096419
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases.
    Genc H; Duyur Cakit B; Nacir B; Saracoglu M; Kacar M; Erdem HR
    Clin Rheumatol; 2007 Jul; 26(7):1104-10. PubMed ID: 17086383
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect.
    Corkill MM; Jobanputra P; Gibson T; Macfarlane DG
    Br J Rheumatol; 1990 Feb; 29(1):41-5. PubMed ID: 1968354
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sulphasalazine (Salazopyrin) in the treatment of enterogenic reactive synovitis and ankylosing spondylitis with peripheral arthritis.
    Mielants H; Veys EM; Joos R
    Clin Rheumatol; 1986 Jan; 5(1):80-3. PubMed ID: 2869851
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating inhibitor bound elastase in patients with ankylosing spondylitis and rheumatoid arthritis and the influence of sulphasalazine treatment.
    Feltelius N; Hällgren R
    Ann Rheum Dis; 1988 Jan; 47(1):10-4. PubMed ID: 2894204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sulfasalazine-Related Hypersensitivity Reactions in Patients With Rheumatic Diseases.
    Cildag S; Senturk T
    J Clin Rheumatol; 2017 Mar; 23(2):77-79. PubMed ID: 28121807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.